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Vasopressin receptors in health and disease. The molecular cloning and
characterization of receptors for the nonapeptide hormone family vaso-
pressin-oxytocin was rapidly followed by the identification of mutations in
the V2 receptor gene segregating with the clinical phenotype in more than
a hundred families with X-linked nephrogenic diabetes insipidus. To-
gether with the recent cloning of the vasopressin-regulated water channel
in the apical membrane of the collecting duct tubule and of the identifi-
cation of rare autosomal recessive nephrogenic diabetes insipidus patients
with mutations in the AQP2 gene, these developments enable carrier
detection and early diagnosis of infants with congenital nephrogenic
diabetes insipidus.
Vasopressin and oxytocin receptors and postreceptor events
Multiple cellular actions of arginine vasopressin and oxytocin
The neurohypophysal hormone arginine vasopressin (AVP) has
multiple actions, including the inhibition of diuresis, contraction
of smooth muscle, platelet aggregation, stimulation of liver glyco-
genolysis, modulation of adrenocorticotropic hormone release
from the pituitary, and central regulation of somatic functions
(thermoregulation, blood pressure) [1]. These multiple actions of
AVP could be explained by the interaction of AVP with at least
three types of G protein-coupled receptors; the Via (vascular
hepatic) and Vib (anterior pituitary) receptors act through phos-
phatidylinositol hydrolysis to mobilize calcium [2], and the V2
(kidney) receptor is coupled to adenylate cyclase [1]. The neuro-
hypophysal hormone oxytocin differs only from AVP by two
amino acids and apparently originates from the same ancestral
gene. Oxytocin induces uterine contraction and milk ejection also
through a G protein-coupled receptor with phosphatidylinositol
hydrolysis and calcium mobilization [11.
Cloning and structural similarities between vasopressin, oxytocin
and vasotocin receptors
Molecular cloning and the expression of vasopressin and oxy-
tocin receptors have confirmed that these receptors belong to the
G protein-coupled receptor family characterized by seven putative
transmembrane helices. It is thought that the transmembrane
columns interact with each other to form a pocket where the
agonist binds to induce the conformation responsible for activat-
ing the G protein, that is, the next component of signalling
pathway. To date, more than ten related complementary DNAs
have been cloned and sequenced: they encode the rat and human
vasopressin Via receptors [3, 4], the human vasopressin Vib (or
V3) receptor [5, 6], the rat and human vasopressin V2 receptors
[7, 81, the rat and human oxytocin receptors [9, 10], the [Lys8]VP
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V2 receptor and the oxytocin receptor from a pig kidney cell line
[11], and the [Arg8] vasotocin receptors from teleost fish and toad
[12]. As demonstrated in Figure 1, these receptors are strikingly
similar in both size and amino acid sequences. The rat Via and the
human oxytocin receptors have 48% similarity with the human V2
receptor. The V2[Lys8]VP receptor from the pig kidney cell line
and the human V2 receptor (V2[Arg8JVP receptor) demonstrate
more than 90% identity within their putative transmembrane
domains, 80% identity for their C-terminal regions, and a rela-
tively low identity of 62% for their N-terminal regions. These
differences could be responsible for different ligand affinities. As
expected, the messenger RNA (mRNA) encoding the Via recep-
tor is abundant in rat liver and kidney and present in brain [3, 13].
V2 receptor transcripts are heavily expressed in cells of the renal
collecting ducts and thick ascending limbs of the loops of Henlé
[14]. RT-PCR [6] and Northern blot [5] analysis showed that the
human V3 receptor was expressed in normal pituitary.
Cellular actions of vasopressin and molecular biology of
nephrogenic diabetes insipidus
The first step in the action of AVP on water excretion is its
binding to arginine-vasopressin type 2 receptors (V2 receptors) on
the basolateral membrane of the collecting duct cells (Fig. 2). The
human V2 receptor gene, AVPR2, is located in chromosome
region Xq28 and has three exons and two small introns [8, 151.
The sequence of the cDNA predicts a polypeptide of 371 amino
acids with a structure typical of guanine-nucleotide (G) protein-
coupled receptors with seven transmembrane, four extracellular,
and four cytoplasmic domains [16] (Fig. 3). The activation of the
V2 receptor on renal collecting tubules stimulates adenylyl cyclase
via the stimulatory G protein (G) and promotes the cyclic
adenosine monophosphate (cAMP)-mediated incorporation of
water channels (aquaporins) into the luminal surface of these
cells. This process is the molecular basis of the vasopressin-
induced increase in the osmotic water permeability of the apical
membrane of the collecting tubule. Aquaporin-1 (AQP1, also
knowns as CHIP, channel-forming integral membrane protein of
28 kDa) was the first protein shown to function as a molecular
water channel [aquaporins reviewed in 171 and is constitutively
expressed in mammalian red cells, renal proximal tubules, thin
descending limbs, and other water permeable epithelia. At the
subcellular level AQP1 is localized in both apical and basolateral
plasma membranes, which may represent entrance and exit routes
for transepithelial water transport. In contrast to AQP2 (vide
infra), limited amounts of AQP1 are localized in membranes of
vesicles or vacuoles. In the basolateral membranes AQP1 is
localized to both basal and lateral infoldings. AQP2 is the
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Fig. 1. Amino acid sequences conserved within
seven members of the A VP-oxytocin-vasotocin
receptor family: hl/1,,, V,,,, V oxy; rat V,,,, V
oxy; [Arg8jvasotocin receptor of the anuran
Xenopus laevis. The receptors share the
sequence FQVLPQ at the 3' end of the second
transmembrane domain. This sequence could
play a major role in ligand binding and signal
transduction. The sequence
FXGPDXLCRXVK at the 3' end of the first
extracellular loop and DCWAXFXXPWG in
the second extracellular loop are also conserved
here and not found in other heptahelix-
receptors. These extracellular sequences are
plausible elements of the ligand recognition
site. Finally, the common motif NPWIY in the
seventh transmembrane domain could be
involved in receptor-mediated endocytosis (data
are from [4]).
Fig. 2. Schematic view of the intracellular action
of the antidiuretic hormone, arginine vasopressin
(A VP). The hormone is bound to the
vasopressin V2 receptor (a G-protein linked
receptor) on the basolateral membrane. AVP
activates adenylate-cyclase increasing the
intracellular concentration of cyclic AMP
(cAMP). The topology of adenylyl cyclasc is
characterized by two tandem repeats of six
hydrophobic putative transmembrane domains
separated by a large cytoplasmic loop and
terminating in a large intracellular tail. Cyclic
AMP generation follows receptor-linked
activation of the heterometric G protein (G)
and interaction of the free Grn-chain with the
adenylyl cyclase catalyst. A cAMP dependent
protein kinase (P1(A) is the target of the
generated cAMP. Cytoplasmic vesicles carrying
the water channel proteins (represented as
homotetrameric complexes [31]) are fused to
the luminal membrane in response to
vasopressin, thereby increasing the water
permeability of this membrane. When
vasopressin is not available, water channels are
retrieved by an endocytic process and water
permeability returns to its original low rate.
AQP3 and AQP4 are expressed on the
basolateral membrane.
vasopressin-regulated water channel in renal collecting ducts. It is
exclusively present in principal cells of inner medullary collecting
duct cells and is diffusely distributed in the cytoplasm in the
euhydrated condition, whereas apical staining of AQP2 is inten-
sified in the dehydrated condition or after vasopressin adminis-
tration, These observations are thought to represent the exocytic
insertion of preformed water channels from intracellular vesicles
into the apical plasma membrane (the shuttle hypothesis) (Fig. 2).
AQP3 is the water channel in basolateral membranes of renal
medullary collecting ducts. AQP4 is abundantly expressed in brain
and could be the osmoreceptor which regulates body water
balance and mediates water flow within the central nervous system.
Docking and fusion of intracellular vesicles with their target
membranes is mediated by a complex array of widely distributed
proteins, extensively studied at the nerve terminal level and
implicated in the synaptic vesicle cycle [reviewed in 18]. Some of
these proteins have also been recently examined in inner medul-
lary collecting duct cells. Synaptobrevin2 (vesicle associated mem-
brane protein 2, VAMP2), a component of the ncuronal SNARE
complex, is expressed in vesicles carrying AQP2, suggesting a role
in vasopressin regulated vesicle trafficking of AQP2 water chan-
nels [19]. A syntaxin isoform has been found in light endosomes
containing AQP2 obtained from the rat kidney papilla [2O.
Proteins involved in vesicular transport have been found in a
preparation from rat kidney enriched in AQP2 containing vesi-
des: a protein of the Rab3 family, a Rab5a protein (proteins of
the Rab3 and Rab5 families are specifically linked to regulated
exocytosis and endocytosis), and a synaptobrevin IT-like protein
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Fig. 3. Schematic representation of the V2 receptor and identification of 68 A VPR2 mutations which include 35 missense, 10 nonsense, 17 frameshift, 2
inframe deletion, I splice-site, and 3 large deletion mutations. The three large deletions are incompletely characterized, and are not included in the Figure.
Predicted amino acids are given as the one letter code. Solid symbols indicate the predicted location of the mutations; an asterisk indicates two different
mutations in the same codon. The names of the mutations were assigned according to the conventional nomenclature [32]. The extracellular (E1 to E1),
cytoplasmic (C1 to C) and transmembrane domains (TM1 to TMv1i) are labeled according to Sharif and Hanley [33]. F1: 98del28, 98ins28, ll3delCT.
TM1: L44F, L44P, L53R, A61V, L62P. TM1 and C1: 253de135, 255de19. C1: 274insG, W71X. TM11: H8OR, L83P, D85 N, V88 M, P95L. E11: R1O6C,
4O2delCT, C112R, R113W. TM 111: Q119X, Y124X, 5126F, Y1285, A132D. C11: R137H, R143P, 528del7, 528delG. TM1: W164S, S167L, S167T. E111:
R181C, G1S5C, R202C, T204 N, 684delTA, Y205C, V206D. TM: Q225X, 753insC. C111: E231X, 763delA, 786delG, E242X, 8O4insG, 8O4delG,
834delA, 855delG. TM1: V277A, V278, Y280C, W284X, A285P, P286R, L292P, W293X. E1: 977delG, 980A—G. TM11: L312X, P322H, P322S,
W323R. C1v: R337X.
[21]. In neuronal and neuroendocrine cells Rab3 proteins are
involved in the fusion of secretory vesicles to the plasma mem-
brane. The identification of a Rab3-like protein in kidney epithe-
hal cells may serve a similar function. Thus, there is now structural
evidence that vasopressin induced antidiuresis is similar to regu-
lated exocytosis in neuronal and non-neuronal secretory cells.
The gene that codes for the water channel of the apical
membrane of the kidney-collecting tubule has been designated
aquaporin-2 (AQP2) and was cloned by homology to the rat
aquaporin of collecting duct [22, 23]. The human AQP2 gene is
located in chromosome region 12q13 and has four exons and three
introns. It is predicted to code for a polypeptide of 271 amino
acids that is organized into two repeats oriented at 1800 to each
other and has six membrane-spanning domains, both terminal
ends located intracellularly, and conserved Asn-Pro-Ala boxes
(Fig. 4). These features are characteristic of the major intrinsic
protein family [17]. Aquaporiri-2 is detectable in urine, and
changes in urinary excretion of this protein can be used as an
index of the action of vasopressin on the kidney [24].
X-linked nephrogenic diabetes insipidus and mutations in the
AVPR2 gene
X-linked nephrogenic diabetes insipidus (MIM 304800 [25]) is
generally a rare disease in which the affected male patients do not
concentrate their urine after the administration of AVP [261.
Because it is a rare, recessive X-linked disease, females are
unlikely to be affected, but heterozygous females exhibit variable
degrees of polyuria and polydipsia because of skewed X, chromo-
some inactivation. In Quebec, the incidence of this disease among
males was estimated to be approximately 4 in 1,000,000. A founder
effect for a particular AVPR2 mutation in Ulster Scot immigrants
resulted in an elevated prevalence of X-linked NDI in their
descendants and was estimated to afflict approximately 24 in 1,000
males in certain communities in Nova Scotia. The W71X mutation
was identified as the cause of NDI in the extended "Hopewell"
kindred and in families in the Canadian Maritime provinces [27].
The W7IX mutations of these patients are likely identical by
descent, although a common ancestor has not been identified in
all cases. Among X-linked NDI patients in North America, the
W71X mutation is more common than any other AVPR2 muta-
tion.
The natural history of untreated disease includes hypernatre-
mia, hyperthermia, mental retardation, and repeated episodes of
dehydration in early infancy. Mental retardation is a consequence
of repeated episodes of dehydration and was present in 73 of 82
patients (89%) in the Crawford and Bode study [27]. Early
recognition and treatment of X-linked NDI with an abundant
intake of water allows a normal life span with normal physical and
mental development [27; Bichet, personal observations].
Sixty-eight putative disease-causing mutations in AVPR2 have
now been reported in 95 presumably unrelated families with
X-linked NDI from diverse ethnic groups (Fig. 3). In addition, 19
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Fig. 4. schematic representation of the
aquaporin-2 protein and identification of four
AQP2 mutations (see test).
new AVPR2 mutations have been identified in 21 independent
families referred to our laboratory during the last year [28]. Of
these, eight were de novo mutations as ascertained by DNA
sequencing and Xq28 haplotype analysis. In X-linked NDI, loss of
mutant alleles from the population occurs because of the in-
creased mortality of affected males, whereas gain of new mutant
alleles occurs by mutation. If affected males with a rare X-linked
recessive disease do not reproduce and if mutation rates are equal
in mothers and fathers, then, at genetic equilibrium, one-third of
the new cases of affected males will be due to new mutations. The
gametic origins of new mutations could be identified or inferred in
18 families and included 5 maternal, 9 grandpaternal, and 2
grandmaternal gametes, 1 great-grandmaternal gamete, and I
gamete that was either of grandpaternal or grandmaternal origin.
Eleven different AVPR2 mutations were observed in more than
one independent NDI family, suggesting that there are mutational
hot spots. Additional evidence for recurrent mutation is the
observation that a mutant allele occurs on different haplotypes
defined by polymorphisms in or very close to the AVPR2 gene.
Seven of the 11 mutations (V88M, R113W, R137H, 5167L,
RI8IC, R202C, and R337X) were single nucleotide substitutions
at a CpU dinucleotide. Methylated CpU dinucleotides are recog-
nized hot spots for mutation. Thirteen of 18 small deletion or
insertion mutations (ito 35 bp) involved direct or complementary
repeats (2 to 9 bp) or strings of 4 to 6 guanines. This finding
suggests that these deletions, like many others that have been
described in other genes, resulted from DNA strand slippage and
mispairing during replication [27].
The cause of loss of function of mutant V2 receptors has been
studied in in vitro expression systems [reviewed in 27, 29].
Truncated polypeptides, which are expected to be nonfunctional,
or absent protein are expected in the case of nonsense mutations
(W71X, Q119X, Y124X, 0225X, E231X, E242X, W284X,
W293X, L312X, and R337X). A missense mutation could result in
misfolding of the protein and trapping in the endoplasmic retic-
utum, or alteration of the binding pocket or the contact surface
that activates the stimulatory U protein. The R137H mutant
protein expressed in cultured kidney cells from African green
monkey (COS cells) from transfected mutant eDNA exhibited a
normal binding affinity for AVP but failed to stimulate the
U/adenylyl cyclase system. The RI 13W mutant eDNA was also
transfected into COS cells and the mutant protein exhibited a
combination of functional defects: lowered affinity for vasopres-
sin, diminished ability to stimulate adenylyl cyclase, and dimin-
ished ability to reach the cell surface. A similar result has been
obtained for the Y2OSC mutant. No adenylyl cyclase activity was
detected in COS cells transfected with eDNA of a nonsense
mutation (Q119X), frameshift mutation (763delA or 85SdelG), or
missense mutations. In addition, functional analysis of AVPR2
mutations provided evidence that the 810de112 mutation is not the
cause of NDI in a patient who had this mutation as well as the
R181C mutation. The R181C mutant receptor had less than half
of the normal adenylyl cyclase activity, and although it was
expressed at the same level as the normal V2 receptor, the EC50
for adenylyl cyclase stimulation was increased presumably due to
its altered structure. More recently, binding, cAMP and immuno-
fluorescence studies allowed for the distinction of three distinct
phenotypes: (1) simple binding impairment at the cell surface; (2)
blocked intracellular transport; (3) ineffective biosynthesis and/or
accelerated degradation of the receptor [29].
Autosomal recessive nephrogenic diabetes insipidus and
mutations in the AQP2 gene
On the basis of dDAVP infusion studies and phenotypic
characteristics of both males and females affected with NDI, a
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non-X-linked form of NDI with a post-receptor (post-cyclic-
AMP) defect was suggested [27]. A patient who presented shortly
after birth with typical features of NDI, but who exhibited normal
coagulation and normal fibrinolytic and vasodilatory responses to
dDAVP was recently shown to be a compound heterozygote for
two missense mutations (R187C and S217P) in the AQP2 gene
(Fig. 4). Three NDI patients from consanguineous matings were
found to be homozygous for missense mutations (R187C or
G64R) or a frameshift mutation (369delC) in the AQP2 gene.
Functional expression studies showed that Xenopus oocytes in-
jected with mutant cRNA had abnormal coefficients of water
permeability, while Xenopus oocytes injected with both mutant
and normal cRNAs had coefficients of water permeability similar
to those of normal constructs alone. These findings provide
conclusive evidence that NDI can be caused by homozygosity for
mutations in the AQP2 gene. The increased frequency of consan-
guinity between normal parents of affected children of both
genders with AQP2 mutations is consistent with autosomal reces-
sive inheritance of a rare genetic disease. More recently, we
obtained preliminary evidence to suggest that both autosomal
dominant and autosomal recessive nephrogenic diabetes insipidus
phenotypes could be secondary to novel mutations in the AQP2
gene [30].
Summary and perspectives
In our study of 75 independently referred families, X-linked
nephrogenic diabetes insipidus is more frequently encountered
(71 families) than autosomal recessive nephrogenic diabetes
insipidus (4 families). We have studied two families with familial
nephrogenic diabetes insipidus with a post-receptor defect as
determined by plasma cAMP measurement after dDAVP infu-
sion, but found no mutations in the open reading frames and
published upstream regulatory sequences of both AVPR2 and
AQP2. This latter observation suggests the existence of at least
one other gene responsible for nephrogenic diabetes insipidus.
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